

08th January, 2025

To, The Manager, BSE Limited **Department of Corporate Services** Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001

Scrip Code - 532384

Subject: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, This is to inform you that, the United States Food & Drug Administration (USFDA) completed inspection of our manufacturing facility situated at Kakinada, Andhra Pradesh during August, 2024 and issued Seven observations.

We further inform you that United States Food & Drug Administration (USFDA) has classified the inspection as "Official Action Indicated" (OAI).

The Company remains committed to work closely with the USFDA and continues to enhance its compliance on an ongoing basis. We will work with the USFDA to resolve these issues at the earliest.

We will keep the stock exchange informed if there is any further information relating to the above in the future.

Kindly take the same on record and acknowledge.

Thanking You, Yours faithfully,

PRADOSH

Digitally signed by PRADOSH RANJAN

RANJAN

Date: 2025.01.08 15:21:20 +05'30'

JENA

For Tyche Industries Limited Pradosh Ranjan Jena **Company Secretary & Compliance Officer**



Regd. Office: H.No. C 21/A, Road No. 9, Film Nagar, Jubilee Hills, Hyderabad - 500 096. Tel: +91-40-2354 1688, Fax: +91-40-2354 0933, E-mail: info@tycheindustries.com

Factory: Door No. 6-223, Sarpavaram, Kakinada, East Godavari Dist.

CIN:L72200TG1998PLC029809